相似文献
1
Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches.
Blood Adv. 2021 Mar 9;5(5):1340-1343. doi: 10.1182/bloodadvances.2020003996.
2
Multiple myeloma: Current advances and future directions.
Best Pract Res Clin Haematol. 2020 Mar;33(1):101155. doi: 10.1016/j.beha.2020.101155. Epub 2020 Feb 5.
3
Plasma cell dedifferentiation in refractory multiple myeloma.
Br J Haematol. 2021 Apr;193(2):212. doi: 10.1111/bjh.17244. Epub 2021 Mar 26.
4
Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2007 Apr;18 Suppl 2:ii44-6. doi: 10.1093/annonc/mdm032.
5
[Results, failures and perspectives in therapy of multiple myeloma].
Vopr Onkol. 2002;48(2):146-52.
6
Maintenance therapy in multiple myeloma.
Clin Adv Hematol Oncol. 2014 Feb;12(2):133-4.
7
[Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs].
Med Clin (Barc). 2016 Dec 2;147(11):e63-e64. doi: 10.1016/j.medcli.2016.09.010. Epub 2016 Oct 27.
8
Multiple myeloma in the era of novel agents.
Semin Hematol. 2009 Apr;46(2):107-9. doi: 10.1053/j.seminhematol.2009.03.001.
9
Cardiovascular Complications of Novel Multiple Myeloma Treatments.
Circulation. 2016 Mar 1;133(9):908-12. doi: 10.1161/CIRCULATIONAHA.115.018351.
10
Multiple myeloma and systemic amyloidosis.
Int J Dermatol. 2008 Feb;47(2):165-7. doi: 10.1111/j.1365-4632.2008.03352.x.
引用本文的文献
1
MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study.
Front Pharmacol. 2025 Apr 4;16:1465814. doi: 10.3389/fphar.2025.1465814. eCollection 2025.
2
Is there a Possible Association between Multiple Myeloma Relapse and Coronavirus Disease 2019 Vaccination? A Case Report.
J Res Pharm Pract. 2024 Sep 26;13(1):27-32. doi: 10.4103/jrpp.jrpp_21_24. eCollection 2024 Jan-Mar.
3
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Blood. 2023 Feb 9;141(6):579-591. doi: 10.1182/blood.2022016782.
4
Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.
Front Oncol. 2022 Jan 14;11:800309. doi: 10.3389/fonc.2021.800309. eCollection 2021.
本文引用的文献
1
Newly Diagnosed Myeloma in 2020.
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-15. doi: 10.1200/EDBK_280221.
2
Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond.
Expert Rev Hematol. 2020 Jun;13(6):669-686. doi: 10.1080/17474086.2020.1756258. Epub 2020 Apr 27.
3
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Future Oncol. 2020 Apr;16(11):631-641. doi: 10.2217/fon-2020-0024. Epub 2020 Mar 6.
4
Multiple Myeloma: Available Therapies and Causes of Drug Resistance.
Cancers (Basel). 2020 Feb 10;12(2):407. doi: 10.3390/cancers12020407.
5
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
J Clin Oncol. 2020 Mar 10;38(8):784-792. doi: 10.1200/JCO.19.01231. Epub 2019 Nov 26.
6
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
7
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol. 2019 Dec;6(12):e616-e629. doi: 10.1016/S2352-3026(19)30167-X. Epub 2019 Oct 14.
8
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
9
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.
Leukemia. 2019 Mar;33(3):730-738. doi: 10.1038/s41375-018-0271-1. Epub 2018 Oct 15.
10
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1.
Zotero 插件